Kynamro's only competition is Juxtapid with a yearly cost of $250,000 as against Kynamro's cost of $176,000.
Sales of Juxtapid for the six months were released on 29th July.
Aegerion achieved $36.0 million in net product sales of JUXTAPID® (lomitapide) capsules in the second-quarter of 2014. 93% of net product sales in the second quarter were from the United States business, representing growth of 29% over net product sales from the U.S. business in the prior quarter of 2014.
ANP Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
